Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 31;19(1):2188857.
doi: 10.1080/21645515.2023.2188857. Epub 2023 Mar 20.

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study

Bo T Hansen  1   2 , Angela S Labberton  3 , Prabhjot Kour  4 , Kristian B Kraft  3
Affiliations

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study

Bo T Hansen et al. Hum Vaccin Immunother. .

Abstract

High and equitable COVID-19 vaccination coverage is important for pandemic control and prevention of health inequity. However, little is known about socioeconomic correlates of booster vaccination coverage. In this cross-sectional study of all Norwegian adults in the national vaccination program (N = 4,190,655), we use individual-level registry data to examine coverage by levels of household income and education of primary (≥2 doses) and booster (≥3 doses) vaccination against COVID-19. We stratify the analyses by age groups with different booster recommendations and report relative risk ratios (RR) for vaccination by 25 August 2022. In the 18-44 y group, individuals with highest vs. lowest education had 94% vs. 79% primary coverage (adjusted RR (adjRR) 1.15, 95%CI 1.14-1.15) and 67% vs. 38% booster coverage (adjRR 1.55, 95% CI 1.55-1.56), while individuals with highest vs. lowest income had 94% vs. 81% primary coverage (adjRR 1.10, 95%CI 1.10-1.10) and 60% vs. 43% booster coverage (adjRR 1.23, 95%CI 1.22-1.24). In the ≥45 y group, individuals with highest vs. lowest education had 96% vs. 92% primary coverage (adjRR 1.02, 95%CI 1.02-1.02) and 88% vs. 80% booster coverage (adjRR 1.09, 95%CI 1.09-1.09), while individuals with highest vs. lowest income had 98% vs. 82% primary coverage (adjRR 1.16, 95%CI 1.16-1.16) and 92% vs. 64% booster coverage (adjRR 1.33, 95%CI 1.33-1.34). In conclusion, we document large socioeconomic inequalities in COVID-19 vaccination coverage, especially for booster vaccination, even though all vaccination was free-of-charge. The results highlight the need to tailor information and to target underserved groups for booster vaccination.

Keywords: Booster vaccine; COVID-19; disparity; social inequity; sociodemographic correlates; socioeconomic correlates; vaccination program; vaccine coverage; vaccine hesitancy; vaccine uptake.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
COVID-19 vaccination coverage for ≥ 2 doses (red bars) and ≥ 3 doses (blue bars), by highest attained education level. (a) Vaccination coverage (%) for individuals aged 18–44 y. (b) Vaccination coverage (%) for individuals aged ≥ 45 y.
Figure 2.
Figure 2.
COVID-19 vaccination coverage for ≥ 2 doses (red bars/circles) and ≥ 3 doses (blue bars/triangles), by household income level. (a) Vaccination coverage (%) for individuals aged 18–44 y. (b) Adjusted relative risks for vaccination with associated 95% confidence intervals among individuals aged 18–44 y. (c) Vaccination coverage (%) for individuals aged ≥ 45 y. (d) Adjusted relative risks for vaccination with associated 95% confidence intervals among individuals aged ≥ 45 y.
See this image and copyright information in PMC

References

    1. Haas EJ, Angulo FJ, McLaughlin JM, Anis, E, Singer, SR, Khan, F, Brooks, N, Smaja, M, Mircus, G, Pan, K, Southern, J.. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–10. doi: 10.1016/S0140-6736(21)00947-8. - DOI - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O’Doherty M, Brown K.. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088. - DOI - PMC - PubMed
    1. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, Wilder-Smith A. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44. doi: 10.1016/S0140-6736(22)00152-0. - DOI - PMC - PubMed
    1. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, Legarth R, Lam JU, Chaine M, Malik AZ, Rasmussen M. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study. PLoS Med. 2022;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. - DOI - PMC - PubMed
    1. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76. doi: 10.1016/S0140-6736(21)02717-3. - DOI - PMC - PubMed

Substances